The Supreme Court sided with government regulators in an important case involving the pharmaceutical industry and patent law. At issue were contracts between "brand-name" pharmaceutical companies and "generic" producers in which the brand-name company paid the generic not to compete. The court said the Federal Trade Commission could challenge such contracts.
High Court Sides With Regulators In Drug Patent Case
By editor • Jun 17, 2013
Originally published on June 17, 2013 4:45 pm